CION Ameerpet
Your FNAC report, explained simply
Bethesda categories — FNAC results explained
Medically reviewed by Dr. Owais Mohammed, Medical Oncologist, MBBS · MD · Last reviewed June 2026
If you have just received a thyroid FNAC report with a Bethesda category on it, this page explains what each number means in plain language. The Bethesda System sorts every thyroid fine-needle result into one of six categories — and each tells you how likely the nodule is to be cancer, and what the next step should be.
- Six thyroid FNAC result categories — what each one means, from benign to malignant
- The chance of cancer — the published risk range for each Bethesda category
- Indeterminate thyroid nodule — what Bethesda III and IV mean, and why most are benign
- Your next step — repeat test, monitoring, molecular test or surgery, decided with you
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What the Bethesda System Means on a Thyroid FNAC Report
When a thyroid nodule is checked, a doctor takes a small sample of cells with a very thin needle — a test called fine needle aspiration cytology, or FNAC. A pathologist then examines those cells under a microscope and writes a report. To keep that report clear and consistent, they use the Bethesda System for Reporting Thyroid Cytopathology.
The system sorts every result into one of six thyroid FNAC result categories, numbered I to VI. Each category carries a different chance of the nodule being cancer, and each points to a recommended next step. The number on your report — not the words alone — is what guides whether you simply follow up, repeat the test, or move towards treatment.
This page walks through all six categories in plain language. If you would like your own report explained, you can book a free consultation — at CION your slides can even be re-read by a pathologist as part of a written second opinion.
Did you know?
Most thyroid nodules that reach an FNAC turn out to be benign (Bethesda category II) — only a minority are cancer. The Bethesda system exists so that doctors anywhere read your result the same way and recommend a consistent next step. (Source: The Bethesda System for Reporting Thyroid Cytopathology, 2nd edition.)
Thyroid FNAC result categories
The Six Bethesda Categories, One by One
Tap any category to see what it means, the published chance of cancer, and the usual next step. The risk figures below are the ranges given in the Bethesda System (2nd edition); your own risk is read alongside your ultrasound and history.
Non-diagnostic or unsatisfactory
What it means: the sample did not contain enough usable cells to give an answer — so it is non-diagnostic, not abnormal. This can happen when a nodule is mostly fluid, very small, or hard to reach. It is a common, harmless outcome, and on its own it is not a sign that anything is wrong.
Chance of cancer: the result is simply uninformative, so no reliable risk can be read from it. Usual next step: repeat the FNAC after a short interval, ideally under ultrasound guidance to target the most solid part of the nodule. A repeat gives a usable result in most cases.
Benign
What it means: the cells look harmless — this is the most common and most reassuring result. It usually points to a benign thyroid condition such as a colloid nodule, a goitre, or non-cancerous thyroiditis. The great majority of nodules that reach FNAC fall here.
Chance of cancer: very low, in the order of around 0–3%. Usual next step: no surgery needed in most cases — simply follow-up, typically with a repeat ultrasound after an interval to make sure the nodule stays stable. Any new growth or change is then reviewed.
Atypia of undetermined significance (AUS) — indeterminate
What it means: this is the first of the indeterminate thyroid nodule categories. The cells look slightly unusual, but not enough to call benign or to suggest cancer. It is one of the most common reasons people feel anxious after an FNAC — yet most nodules in this group turn out to be benign once fully assessed.
Chance of cancer: roughly 10–30%, depending on the centre and how the result is read. Usual next step: a careful review of your ultrasound, often a repeat FNAC, a molecular (gene) test where available, or a diagnostic surgery to remove and examine the nodule. The path is chosen with you.
Follicular neoplasm — indeterminate
What it means: the cells show a follicular pattern that the cytology test alone cannot label as benign or cancer — the two can look identical down a microscope. This is the second indeterminate category. Many of these nodules are benign follicular adenomas, but a portion are follicular cancers, so the difference matters.
Chance of cancer: approximately 25–40%. Usual next step: because FNAC cannot separate the two reliably, the standard answer is a diagnostic surgery (usually removing one half of the thyroid) so the nodule can be examined in full. A molecular test may be used first where it can safely avoid an operation.
Suspicious for malignancy
What it means: the cells show several features of cancer, but not quite enough for the pathologist to call it definite. It points strongly towards a thyroid cancer — most often the papillary type — without giving a final confirmation on cytology alone. A result here is taken seriously, but it is also highly treatable when acted on early.
Chance of cancer: high, in the region of 50–75%. Usual next step: surgery is the usual recommendation. The exact operation depends on the nodule, the ultrasound findings and your health, and at CION every such case is reviewed by a tumour board so the plan is made by a team, not one opinion.
Malignant
What it means: the cells clearly show cancer — the FNAC confirms a thyroid malignancy. This usually allows the team to name the type, most commonly papillary thyroid cancer, and to plan treatment directly. Receiving this result is understandably hard, but most thyroid cancers are among the most treatable of all cancers when managed early.
Chance of cancer: very high, around 97–99%. Usual next step: surgery to remove part or all of the thyroid, with the precise plan set by a tumour board. Some cases also need radioactive iodine afterwards. Your treatment path is explained fully, with transparent costs and clear next steps.
A category is a starting point, not a verdict. Your specialist reads it alongside your ultrasound, your symptoms and your risk before recommending anything. Talk to a CION specialist to have your own result explained.
Why the Bethesda Number Matters More Than the Words
It is natural to scan a report for the words "benign" or "cancer" — but with a thyroid FNAC, the Bethesda number carries more meaning. Two reports can both look worrying at a glance, yet a category II and a category VI lead to completely different paths.
The number tells your specialist three things at once: how likely cancer is, how confident the test is, and what the recommended next step should be. That is why an unhurried conversation about your specific category is worth far more than searching the report line by line.
If your report is indeterminate — Bethesda III or IV — remember that most indeterminate thyroid nodules are benign once fully assessed. The aim of every next step is simple: to avoid missing a cancer, and to avoid operating on a harmless lump.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
An Indeterminate Result Is Not a Diagnosis
Most indeterminate thyroid nodules turn out to be benign. We walk this journey with you — reviewing your slides, your ultrasound and your history before any decision, with no unnecessary tests.
What Happens Next, Step by Step
Whatever your Bethesda category, the pathway from an FNAC result to a clear plan follows the same calm, ordered steps. Nothing is rushed, and you are part of every decision.
Your result is read in context
Your specialist reads the Bethesda category alongside your neck ultrasound, your symptoms and your personal risk. The same number can mean different things depending on how the nodule looks and how it has behaved over time.
A repeat test, if the sample was unclear
If the FNAC was non-diagnostic (Bethesda I) or borderline, the simplest next step is often to repeat it under ultrasound guidance. A better-targeted sample frequently gives a clear, usable answer the second time.
Extra clarity for an indeterminate nodule
For an indeterminate thyroid nodule (Bethesda III or IV), a molecular (gene) test can sometimes tell whether surgery is truly needed — helping safely avoid an operation when the chance of cancer is low.
Review by a tumour board
Where a result points towards cancer, your case is discussed by a team — medical, surgical and pathology specialists together — so the plan is a tumour-board decision, not one doctor's opinion.
A clear plan, explained to you
Finally, you receive a plain-language plan — whether that is follow-up, a repeat test, a molecular test, or surgery — with transparent costs and clear next steps. You can read more on our thyroid cancer treatment page.
Did you know?
For an indeterminate thyroid nodule (Bethesda III or IV), molecular testing can help separate the nodules that genuinely need surgery from those that can safely be watched — reducing the number of diagnostic operations on lumps that turn out to be benign. (Source: NCCN Clinical Practice Guidelines — Thyroid Carcinoma.)
Understanding an Indeterminate Thyroid Nodule (Bethesda III & IV)
The indeterminate categories cause the most worry, because they neither rule cancer in nor rule it out. The important thing to hold on to is that most indeterminate thyroid nodules are not cancer — they simply could not be settled by cytology alone.
Bethesda III (AUS). The cells are mildly atypical. Often the answer is a careful ultrasound review, a repeat FNAC, or a molecular test — surgery is not always needed, and many of these nodules are eventually confirmed benign.
Bethesda IV (follicular neoplasm). Here the cell pattern cannot be told apart from cancer down a microscope, so a diagnostic surgery — usually removing one half of the thyroid — is the standard way to be certain. A molecular test may be used first where it can safely avoid an operation.
The right route depends on your nodule's ultrasound features, its size, your age and your preferences. At CION the route is decided with you, not for you — and only after your slides and scans have been reviewed properly. You can also explore the wider thyroid cancer hub for related guidance.
Why Patients Bring Their FNAC Report to CION
If you want your Bethesda result explained properly — and a next step that is right for you, not just routine — here is what you can expect at CION.
- Free written second opinion — bring your FNAC report and slides can be re-read by a pathologist at no cost
- Free 45-minute consultation — unhurried time to explain your category and answer every question
- No unnecessary tests, ever — a repeat FNAC, molecular test or surgery is advised only when it is genuinely needed
- Tumour board for every patient — your case is reviewed by a team, not one doctor's opinion
- 35+ centres across Telangana & AP — expert review close to home, with less travel
- Transparent costs and clear next steps — decisions for healing, not billing
A Bethesda result is a starting point, not the final word. Book a free consultation and have yours explained by a specialist who has time to listen.
From our patients
People Who Brought Us a Worrying Report — and What Happened Next
Real stories from patients who had an FNAC result explained, got the right next step, and walked the journey with our team.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Bethesda Thyroid FNAC Results — Your Questions Answered
What does the Bethesda system mean on a thyroid FNAC report?
The Bethesda System for Reporting Thyroid Cytopathology is a standard way pathologists describe the cells taken from a thyroid nodule during an FNAC test. It sorts the result into one of six categories, numbered I to VI, and each category carries a different chance of the nodule being cancer. The system exists so that doctors anywhere read a thyroid FNAC report the same way and recommend a consistent next step. Your Bethesda category — not the word "cancer" or "benign" alone — is what guides whether you need a repeat test, monitoring, a molecular test, or surgery.
Which Bethesda categories are benign and which suggest cancer?
Bethesda category II means benign — the most common and most reassuring result, usually needing only follow-up. Categories V (suspicious for malignancy) and VI (malignant) point strongly towards cancer and usually lead to surgery. Category I means the sample was non-diagnostic and the test often needs to be repeated. Categories III and IV are the indeterminate thyroid nodule group — neither clearly benign nor clearly cancer — and need an individual plan. The category number tells your doctor how likely cancer is and what to do next, but only your specialist can interpret it in the context of your ultrasound and history.
What is an indeterminate thyroid nodule?
An indeterminate thyroid nodule is one whose FNAC result falls into Bethesda category III or IV — the cells look abnormal in some way but do not clearly show cancer or clearly show a benign change. It is one of the most common reasons people feel anxious after an FNAC, because the report neither rules cancer in nor rules it out. Most indeterminate nodules turn out to be benign when fully assessed. The next step is usually a careful review of your ultrasound, sometimes a repeat FNAC, a molecular (gene) test where available, or a diagnostic surgery to remove and examine the nodule. The right path is decided with you, not for you.
Does a Bethesda 3 or 4 result mean I have cancer?
No — a Bethesda category III or IV result does not mean you have cancer. These are the indeterminate categories, and most nodules in this group are found to be benign once they are fully assessed. The result simply means the FNAC could not give a clear yes-or-no answer, so more information is needed. Depending on your nodule's ultrasound features and your personal risk, your specialist may suggest a repeat FNAC, a molecular test, close monitoring, or removing the nodule with surgery to be certain. The aim is to avoid both missing a cancer and operating on a harmless lump.
What happens after a Bethesda 1 non-diagnostic FNAC?
A Bethesda category I result means the sample did not contain enough usable cells to give an answer — it is non-diagnostic, not abnormal. This can happen if the nodule is mostly fluid, very small, or hard to reach. The usual next step is to repeat the FNAC, ideally with ultrasound guidance to target the most solid part of the nodule, after a short interval. A repeat test gives a usable result in most cases. A non-diagnostic result is common and is not, by itself, a sign that anything is wrong.
Will a Bethesda 5 or 6 result always need surgery?
A Bethesda category V (suspicious for malignancy) or VI (malignant) result carries a high chance of thyroid cancer, so surgery is the usual recommendation. The exact operation — removing half the thyroid or all of it — and whether any neck lymph nodes are addressed, depends on the type of cancer, the size of the nodule, the ultrasound findings, and your overall health. At CION every such case is reviewed by a tumour board, so the plan is made by a team rather than a single opinion. Even a malignant thyroid FNAC result is, in most cases, highly treatable when managed early.
Is a thyroid FNAC test painful, and how long do results take?
A thyroid FNAC uses a very thin needle and is usually no more uncomfortable than a routine blood test — most people describe a brief sting or pressure rather than pain. It takes only a few minutes, needs no cuts or stitches, and you can go home straight away. The cells are then examined by a pathologist and reported using the Bethesda system, with results typically available within a few days. Doing the FNAC under ultrasound guidance improves the chance of a clear, usable sample the first time.
Can a Bethesda thyroid FNAC result change on a repeat test?
Yes, it can. A repeat FNAC sometimes moves a result into a clearer category — for example a non-diagnostic (Bethesda I) sample becoming benign (II) on a better-targeted repeat, or an indeterminate result being clarified. This is exactly why repeat testing, ultrasound-guided sampling, and in some cases molecular testing are part of the pathway. A single FNAC result is one piece of the picture; your specialist reads it alongside your ultrasound, your symptoms, and your risk factors before recommending anything.
Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The malignancy-risk ranges shown reflect figures published in the Bethesda System for Reporting Thyroid Cytopathology and may vary between laboratories; your own result must be interpreted by a qualified specialist alongside your ultrasound and history. This page is periodically reviewed and updated by CION's medical team in line with current clinical guidelines.
Explore more
Thyroid Cancer Topics
Browse our complete guide to thyroid cancer — types, symptoms, causes, tests, stages and treatment. Tap any topic to read more.
Treatment & Specialist Care
Types of Thyroid Cancer
Symptoms & Warning Signs
Causes & Risk Factors
Tests & Diagnosis
Stages, Survival & Prognosis
Treatment & Procedures
Thyroidectomy Surgery
Thyroid Lobectomy
Neck Dissection
Radioactive Iodine (RAI)
Low-Iodine Diet for RAI
Targeted Therapy
External Beam Radiation
Does It Need Chemotherapy?
Treatment Without Surgery
Active Surveillance
Hormone Replacement & TSH
RAI-Refractory Disease
Anaplastic Cancer Treatment
Treatment Side Effects